ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Mountain Crest Acquisition Corporation V

Mountain Crest Acquisition Corporation V (MCAG)

11,18
0,00
(0,00%)
Fermé 21 Septembre 10:00PM
11,18
0,00
( 0,00% )
Avant marché: 10:15AM

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

Dernier
11,18
Prix Achat
10,71
Prix Vente
11,37
Volume échangé
-
0,00 Fourchette du Jour 0,00
10,47 Plage de 52 semaines 11,37
Cap du marché
Clôture Veille
11,18
Ouverture
-
Dernière Transaction
Dernière heure de transaction
-
Volume financier
-
VWAP
-
Volume moyen (3 m)
2 116
Actions en circulation
3 170 221
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-15,75
Bénéfice par action (BPA)
-0,71
Chiffre d'affairess
-
Bénéfice net
-2,25M

À propos de Mountain Crest Acquisition Corporation V

Mountain Crest Acquisition Corp V is a blank check company. Mountain Crest Acquisition Corp V is a blank check company.

Secteur
Blank Checks
Industrie
Blank Checks
Siège social
Wilmington, Delaware, USA
Fondé
-
Mountain Crest Acquisition Corporation V est coté dans le secteur Blank Checks de la NASDAQ avec le ticker MCAG. Le dernier cours de clôture d'Mountain Crest Acquisiti... était de US$11,18. Au cours de la dernière année, les actions de Mountain Crest Acquisiti... ont été négociées dans une fourchette de prix de US$ 10,47 à US$ 11,37.

Mountain Crest Acquisiti... compte actuellement 3 170 221 actions en circulation. La capitalisation boursière d'Mountain Crest Acquisiti... est de US$35,44 million. Mountain Crest Acquisiti... a un ratio cours/bénéfice (ratio PE) de -15.75.

MCAG Dernières nouvelles

Mountain Crest Acquisition Corp. V Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Reports on Form 10-Q and Makes Progress Towards Regaining Compliance

NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) --  Mountain Crest Acquisition Corp. V (the “Company”) (NASDAQ: MCAG), today announced that it received an expected deficiency notification letter from...

CUBEBIO Announces Business Combination Agreement With Mountain Crest V to Become Publicly Listed

NEW YORK, USA and SEOUL, Korea, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V, a Delaware corporation formed as a special purpose acquisition company (“Mountain Crest V”...

Mountain Crest Acquisition Corp. V Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K and Quarterly Report on Form 10-Q

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V (NASDAQ: MCAG, the “Company”) today announced that it received an expected deficiency notification letter from the...

CUBEBIO Co., Ltd. entered into terms relating to a potential business combination with Mountain Crest Acquisition Corp. V

NEW YORK, USA and SEOUL, Korea, May 02, 2024 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V, a Delaware corporation (“Mountain Crest V”), that is a Nasdaq-listed (Nasdaq: MCAG) special...

Mountain Crest Acquisition Corp. V Announces Listing Transfer to the Nasdaq Capital Market

NEW YORK, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V (Nasdaq: MCAG) (the “Company”) announced today that it has received approval from the Nasdaq Stock Market...

AUM Biosciences Doses First Patient in Phase 2 Clinical Trial of AUM001 in Metastatic Colorectal Cancer

SINGAPORE and BETHESDA, Md., May 30, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotechnology company focused on discovering and developing precision...

AUM Biosciences to Participate in Inaugural EF Hutton Global Conference

SINGAPORE and BETHESDA, Md., April 26, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotechnology company focused on advancing a pipeline of precision...

AUM Biosciences Receives FDA Orphan Drug Designation for AUM302 for the Treatment of Neuroblastoma

SINGAPORE and BETHESDA, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotech company focused on discovering and developing precision oncology...

AUM Biosciences Receives Human Research Ethics Committee Approval to Commence Phase II Clinical Trial of AUM001 for Treatment of Metastatic Colorectal Cancer in Australia

SINGAPORE and BETHESDA, Md., Nov. 15, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing a clinical stage candidate and a broader...

AUM Biosciences to Participate in BioCentury-BayHelix East-West BioPharma Summit

SINGAPORE and BETHESDA, Md., Nov. 04, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing a clinical-stage pipeline of precision...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.16-1.4109347442711.3411.3411.175711.17963022CS
40.373.4227567067510.8111.3710.81571711.09592193CS
120.191.72884440410.9911.3710.71211611.06455286CS
260.383.5185185185210.811.3710.47136010.99414049CS
520.534.976525821610.6511.3710.4782610.93997503CS
156-0.82-6.8333333333312129.6988429.96086364CS
260-0.82-6.8333333333312129.6988429.96086364CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
NUKKNukkleus Inc
US$ 0,3604
(69,60%)
13,79M
SOXMTradr 2X Long SOXX Monthly ETF
US$ 36,96
(58,98%)
44
LGCBLinkage Global Inc
US$ 0,6354
(51,90%)
9,32M
NVVENuvve Holding Corporation
US$ 5,62
(43,37%)
732,37k
LGHLWLion Group Holding Ltd
US$ 0,008
(33,33%)
12
PRFXPainReform Ltd
US$ 0,59
(-23,49%)
15,68k
ZJYLJin Medical International Ltd
US$ 3,20
(-21,57%)
21,54k
SMXTSolarMax Technology Inc
US$ 0,7029
(-19,75%)
200
ADTXAditxt Inc
US$ 0,3101
(-18,95%)
58,13k
CJETChijet Motor Company Inc
US$ 2,28
(-18,57%)
750
NUKKNukkleus Inc
US$ 0,3604
(69,60%)
13,79M
LGCBLinkage Global Inc
US$ 0,6472
(54,72%)
9,32M
MAXNMaxeon Solar Technologies Ltd
US$ 0,0776
(-15,19%)
3,23M
GSIWGarden Stage Ltd
US$ 1,63
(21,64%)
2,99M
INTCIntel Corporation
US$ 22,61
(3,53%)
1,76M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées